PubRank
Search
About
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response (EDI-PIO)
Clinical Trial ID NCT02852486
PubWeight™ 0.00
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT02852486
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Lancet Oncol
2010
8.80
2
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Blood
2013
4.85
3
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
Blood
2006
3.84
4
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
J Clin Oncol
2013
3.56
5
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
J Natl Cancer Inst
2011
3.51
6
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Blood
2013
3.23
7
Standardized definitions of molecular response in chronic myeloid leukemia.
Leukemia
2012
2.80
8
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Nature
2015
2.45
9
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Leukemia
2010
1.97
10
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
Leuk Res
2012
1.60
11
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
Haematologica
2011
1.32
12
Peroxisome proliferator-activated receptor gamma in malignant diseases.
Crit Rev Oncol Hematol
2006
1.21
13
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
Blood
2013
1.15
14
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Am J Hematol
2013
1.06
15
Curing chronic myeloid leukemia.
Curr Hematol Malig Rep
2012
0.79
Next 100